Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IPH4502 · 1 trial · 1 indication
To evaluate the incidence of AEs, SAEs, TEAEs, and DLTs.
| Arm | Type | Description |
|---|---|---|
| IPH4502 Monotherapy | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| IPH4502 | DRUG | Part 1 (dose escalation) and Part 2 (dose optimization) |
Main Inclusion Criteria: * Histologically confirmed, unresectable, locally advanced or metastatic solid tumors that are known to express Nectin-4 * Prior systemic treatment for locally advanced or metastatic disease, yet no therapy with demonstrated clinical benefit for the tumor type is available....
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
IPH4502 is an investigational small molecule being developed for the treatment of advanced or metastatic solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with advanced solid tumors to evaluate its safety and tolerability.
IPH4502 targets Nectin-4, a protein involved in cell adhesion that is expressed on the surface of certain tumor cells. By targeting Nectin-4, IPH4502 is designed to interfere with tumor cell growth and survival. This mechanism is being evaluated in the context of advanced or metastatic solid tumors.
IPH4502 is being developed by Innate Pharma S.A., a biopharmaceutical company. The company is listed on the stock exchange under the ticker symbol IPHA. Innate Pharma is conducting clinical trials to evaluate the safety and efficacy of IPH4502 in patients with advanced solid tumors.
IPH4502 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities for commercial use. The Phase 1 trial is designed to assess the safety, tolerability, and pharmacokinetics of IPH4502 in patients with advanced or metastatic solid tumors.
IPH4502 is being evaluated in a Phase 1 clinical trial with the identifier NCT06781983. This trial is titled 'Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors' and is currently active but not recruiting participants. The study aims to enroll 145 patients and is being conducted in the United States and France.
No, IPH4502 is not the same as Nectin-4. Nectin-4 is the molecular target of IPH4502, meaning IPH4502 is designed to interact with Nectin-4. IPH4502 is a small molecule drug candidate, while Nectin-4 is a protein found on the surface of cells. The drug is being studied for its effects on tumors that express Nectin-4.